Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Assets (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Assets for 6 consecutive years, with $340.1 million as the latest value for Q4 2025.

  • Quarterly Assets fell 30.72% to $340.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $340.1 million through Dec 2025, down 30.72% year-over-year, with the annual reading at $340.1 million for FY2025, 30.72% down from the prior year.
  • Assets hit $340.1 million in Q4 2025 for Lyell Immunopharma, down from $408.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.2 billion in Q2 2021 to a low of $340.1 million in Q4 2025.
  • Historically, Assets has averaged $781.4 million across 5 years, with a median of $795.0 million in 2023.
  • Biggest five-year swings in Assets: rose 24.13% in 2021 and later crashed 41.08% in 2025.
  • Year by year, Assets stood at $1.1 billion in 2021, then fell by 16.84% to $937.6 million in 2022, then decreased by 20.0% to $750.0 million in 2023, then plummeted by 34.55% to $490.9 million in 2024, then crashed by 30.72% to $340.1 million in 2025.
  • Business Quant data shows Assets for LYEL at $340.1 million in Q4 2025, $408.0 million in Q3 2025, and $385.5 million in Q2 2025.